More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects.
Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may benefit. However, the program’s results are limited by the heterogeneity of the MDS patient population and sponsor’s trial design.
Since there is an immune component to some subtypes of MDS, some patients may benefit from immunotherapies, but researchers will need to find appropriate patient sub-populations.
HDAC inhibitors may have promise in combination with other agents but have disappointed in single-agent trials.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.